Serological survey of viral hepatitis markers among newly diagnosed patients with HIV/AIDS in China

HIV Medicine

Volumn 14, Issue 3, 2013, Pages 167-175

  Shen, Yz ^a   Wang, Zy ^a   Qi, Tk ^a   Jiang, Xy ^a   Song, W ^a   Tang, Y ^a   Wang, Jr ^a   Liu, L ^a   Zhang, Rf ^a   Zheng, Yf ^a   Dai, Zs ^a   Lu, Hz ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

AIDS; Hepatitis B virus; Hepatitis C virus; Liver function; Seroepidemiological survey

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHINA; DISEASE MARKER; FEMALE; HEALTH SURVEY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; SEROPREVALENCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; BIOLOGICAL MARKERS; CHINA; DNA, VIRAL; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HIV SEROPOSITIVITY; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES;

EID: 84873278167     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.01048.x     Document Type: Article

References (31)

1. Reuter S, Oette M, Wilhelm FC etal. Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients. Med Microbiol Immunol 2011; 200: 39-49.
2. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: S6-S9.
3. Monica F, Lirussi F, Pregun I, Vasile F, Fabris L, Okolicsanyi L. Hepatitis C virus infection in a resident elderly population: a 10-year follow-up study. Dig Liver Dis 2006; 38: 336-340.
4. Thomas DL. Growing importance of liver disease in HIV-infected persons. Hepatology 2006; 43 (Suppl 1): S221-S229.
5. Cacoub P, Geffray L, Rosenthal E etal. Mortality among human immunodeficiency virusinfected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001; 32: 1207-1214.
6. Rockstroh JK. Influence of viral hepatitis on HIV infection. J Hepatol 2006; 44: S25-S27.
7. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48: 353-367.
8. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008; 197 (Suppl 3): S279-S293.
9. Kaplan JE, Benson C, Holmes KH etal. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58 (RR-4): 1-207.
10. Hasse B, Ledergerber B, Furrer H etal. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53: 1130-1139.
11. Kumar R, Singla V, Kacharya S. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients. Trop Gastroenterol 2008; 29: 136-147.
12. Tien PC, Veterans Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Office. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol 2005; 100: 2338-2354.
13. Zhou S, Zhao Y, He Y etal. Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005-2009. J Acquir Immune Defic Syndr 2010; 54: 191-196.
14. Bhargava A, Singh DK, Rai R. Seroprevalence of viral co-infections in HIV infected children of Northern India. Indian J Pediatr 2009; 76: 917-919.
15. Tankhiwale SS, Khadase RK, Jalgoankar SV. Seroprevalence of anti-HCV and hepatitis B surface antigen in HIV infected patients. Ind J Med Microbial 2003; 21: 268-270.
16. Mohammadi M, Talei G, Sheikhian A etal. Survey of both hepatitis B virus (HBsAg) and hepatitis C virus (HCV-Ab) coinfection among HIV positive patients. Virol J 2009; 6: 202.
17. Jobarteh M, Malfroy M, Peterson I etal. Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Virol J 2010; 7: 230.
18. Nagu TJ, Bakari M, Matee M. Hepatitis A, B and C viral co-infections among HIV-infected adults presenting for care and treatment at Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health 2008; 8: 416.
19. Saillour F, Dabis F, Dupon M etal. Prevalence and determinants of antibodies to hepatitis C virus andmarkers for hepatitis B virus infection in patients with HIV infection in Aquitaine. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. BMJ 1996; 313: 461-464.
20. Wu J, Huang J, Xu D, Lu C, Deng X, Zhou X. Infection status and risk factors of HIV, HBV, HCV, and syphilis among drug users in Guangdong, China - a cross-sectional study. BMC Public Health 2010; 10: 657.
21. von Diemen L, De Boni R, Kessler F, Benzano D, Pechansky F. Risk behaviors for HCV- and HIV-seroprevalence among female crack users in Porto Alegre, Brazil. Arch Womens Ment Health 2010; 13: 185-191.
22. Thomas DL, Leoutsakas D, Zabransky T, Kumar MS. Hepatitis C in HIV-infected individuals: cure and control, right now. J Int AIDS Soc 2011; 14: 22.
23. Mbougua JB, Laurent C, Kouanfack C etal. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health 2010; 10: 105.
24. Guitton E, Montastruc JL, Lapeyre-Mestre M, French Network of Pharmacovigilance Centres. Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. Eur J Clin Pharmacol 2006; 62: 243-249.
25. Pol S, Lebray P, Vallet-Pichard A. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis 2004; 38 (Suppl 2): S65-S72.
26. Sterling RK, Chiu S, Snider K, Nixon D. The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig Dis Sci 2008; 53: 1375-1382.
27. Kovari H, Ledergerber B, Battegay M etal. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. Clin Infect Dis 2010; 50: 502-511.
28. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7: 402-409.
29. Rockstroh JK, Spengler U. HIV and hepatitis C virus co-infection. Lancet Infect Dis 2004; 4: 437-444.
30. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995; 9: 1131-1136.
31. Gupta S, Singh S. Occult Hepatitis B Virus infection in ART-Naive. HIV-Infected Patients seen at a Tertiary Care.Centre in North India. BMC Infect Dis 2010; 10: 53.